Balancing Innovation and Drug Pricing in Global Cancer Care

Jack West, MD, Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, provide a definition for financial toxicity.

Experts in various specialties of oncology management share their insights on the role of financial toxicity on making treatment decisions for patients.

Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, discuss personalized treatment plans based on innovative therapies and affordability.

Jack West, MD, and Gilberto Lopes, MD, share their thoughts on the impact of payers when dealing with the cost of treatments.

Mark Socinski, MD, Gilberto Lopes, MD, and Jack West, MD, provide an overview of the role of EGFR-targeted TKIs in NSCLC and the costs.

Experts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.

A panel of experts discuss treatment options based on efficacy and out-of-pocket cost for patients.

Experts in cancer care management review PD-1/PD-L1 immunotherapy for patients with NSCLC and GI cancers.

Gilberto Lopes, MD, Jack West, MD, and Mark Socinski, MD, provide their insight on the pharmacoeconomic considerations for immunotherapy.

A panel of experts in cancer treatment review the need for PD-1/PD-L1 testing for immunotherapy.

Mark Socinski, MD, and Jack West, MD, review the GEMSTONE-301 and GEMSTONE-302 trials.

Jack West, MD, and Gilberto Lopes, MD, share their thoughts on mitigating strategies of therapy associated with financial toxicity.

A panel of experts debate the cost of innovation vs disruptive pricing of therapy.

Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.